- The Takeda Oncology Company today announced the publication of results from the 682 patient, randomized, Phase III VISTA(1) trial in this week's edition of the New England Journal of Medicine
- The results showed a significant survival benefit and a 30% complete remission (CR) rate with VELCADE, melphalan and prednisone (VcMP) compared to 4% for melaphalan and prednisone (MP) alone in previously untreated multiple myeloma patients
- "These data demonstrate that treatment with VELCADE plus melphalan and prednisone leads to a survival benefit and a high complete remission in previously untreated patients with multiple myeloma," said Professor Jesus San Miguel, M.D., Ph.D., Hematology Department Head, University Hospital of Salamanca and Principal Investigator of the trial. "The combination of VELCADE plus melphalan and prednisone is an important new option for these patients."

Other headlines for [4502.JP]

• 4502.JP 11/26/2008 02:04am
  Takeda Pharmaceutical Co Ltd Authorizes ¥50B share buyback program (1.35% of shares outstanding)
  
• 4502.JP 11/24/2008 06:52pm
  Takeda Pharmaceutical Co Ltd Confirms Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout- A panel of medical experts on Monday recommended approval for more...
  
• 4502.JP 11/24/2008 03:22pm
  Takeda Pharmaceutical Co Ltd FDA advisory panel supports approval of gout drug from Takeda
  
• 4502.JP 11/21/2008 02:02am
  Takeda Pharmaceutical Co Ltd Submits application for Diabetes drug in Europe- Announced that Takeda Global Research & Development Centre (Europe), submitted a marketing authorization application for a prolonged-release more...
  
• AMGN 11/19/2008 06:57pm
  Amgen Inc Enrollment in Phase III MONET1 trial has been temporarily suspended- Enrollment in the Phase III MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the more...
  

Healthcare sector headlines

• GNBT Today 09:30am
  Generex Biotechnology Announces Positive Results of Metformin Chewing Gum Trial- Results of this fully compliant ICH-GCP conducted study indicate that the MetControl Metformin chewing gum and traditional Metformin tablets more...
  
• Today 09:30am
  Fed sets overnight reverse repos, accepts $25B
  
• 4568.JP Today 09:28am
  Daiichi Sankyo Co Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology- Results from three studies of its investigational molecule, DU-176b, will more...
  
• GENZ Today 09:22am
  Genzyme Corp European Patent on cross-linked Gel Slurries has been revoked by EPO board of appeal- Announces that the opposition they filed against European Patent EP 0466300 B1 to Genzyme Corporation has been more...
  
• NABI Today 09:15am
  Nabi Biopharmaceuticals Increases patent portfolio with receipt of two patents for components of PentaStaph- European Patent Office issued Patent EP No. 0 925 073 that provides composition-of-matter protection in the EU more...